Glutathione

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine; GSH) is a ubiquitous tripeptide thiol present in virtually all mammalian cells at intracellular concentrations of 1 to 10 millimolar, constituting the single most abundant non-protein sulfhydryl compound in animal tissues and the central node of cellular redox homeostasis. First isolated by Sir Frederick Gowland Hopkins in 1921 from yeast, blood, and muscle tissue and subsequently characterized as a gamma-linked glutamyl-cysteinyl-glycine tripeptide by Hopkins and colleagues over the following decade, glutathione occupies a singular position in biochemistry: it is simultaneously the principal intracellular reductant maintaining the thiol-disulfide balance of cytosolic and mitochondrial protein pools; the obligate cofactor for glutathione peroxidases (GPx1 through GPx8), glutathione S-transferases (GST alpha, mu, pi, theta, sigma, kappa, omega, and zeta classes), and glutaredoxins; and the substrate for phase II xenobiotic conjugation reactions that render electrophilic metabolites water-soluble for biliary and renal excretion. The reduced form (GSH) predominates under physiological conditions, typically exceeding the oxidized disulfide form (GSSG) by a ratio of 100:1 in the cytosol, with the GSH/GSSG redox couple establishing the electrochemical set point against which cellular redox-sensitive signaling cascades operate, including nuclear factor erythroid 2-related factor 2 (Nrf2) activation, NF-kappaB modulation, and apoptosis signal-regulating kinase 1 (ASK1) regulation.

Biosynthesis proceeds through two sequential ATP-dependent enzymatic steps: gamma-glutamylcysteine ligase (GCL, formerly gamma-glutamylcysteine synthetase) catalyzes the rate-limiting condensation of L-glutamate and L-cysteine via an atypical gamma-carboxyl peptide bond, and glutathione synthetase (GSS) subsequently ligates glycine to the gamma-glutamylcysteine dipeptide. Both enzymes are transcriptionally regulated by the Nrf2-Keap1-ARE (antioxidant response element) pathway, establishing a feedback loop in which oxidative or electrophilic stress induces Nrf2 nuclear translocation, upregulates GCL and GSS expression, and thereby increases glutathione synthesis capacity. Cysteine availability is typically the rate-limiting substrate for biosynthesis, a constraint that underwrites the therapeutic rationale for N-acetylcysteine (NAC) as an indirect glutathione precursor strategy.

The pharmacokinetics of exogenous glutathione are dominated by poor oral bioavailability. The intact tripeptide is a substrate for gamma-glutamyltransferase (GGT) at the intestinal brush border and for intraluminal peptidases, resulting in extensive presystemic hydrolysis. Early pharmacokinetic studies in humans reported negligible increases in plasma or erythrocyte glutathione after single oral doses of reduced glutathione. However, a landmark 2015 randomized, double-blind, placebo-controlled trial by Richie et al. demonstrated that chronic oral supplementation at 250 mg or 1,000 mg for six months produced significant, dose-dependent increases in glutathione stores in erythrocytes (up to 35 percent), plasma, lymphocytes, and buccal mucosal cells, with an associated twofold increase in natural killer cell cytotoxicity in the high-dose group. These findings, together with subsequent work on liposomal, sublingual, and S-acetyl glutathione delivery systems that partially circumvent presystemic hydrolysis, have rekindled interest in direct glutathione supplementation as a complement to the established precursor strategy.

Clinically, glutathione depletion has been documented in a broad spectrum of disease states characterized by chronic oxidative stress, including Parkinson disease (40 percent depletion in the substantia nigra at preclinical stages), nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, HIV/AIDS, cystic fibrosis, and age-related decline. Interventional evidence remains modest relative to the scope of the preclinical and epidemiological literature. In Parkinson disease, the Sechi et al. (1996) open-label study of intravenous glutathione (600 mg in the published literature for 30 days) reported a 42 percent mean improvement in disability scores with effect persisting 2 to 4 months, but the Hauser et al. (2009) randomized, double-blind pilot trial of intravenous glutathione (1,400 mg in the published literature for 4 weeks) did not achieve statistical significance on the primary UPDRS endpoint, though a trend toward symptomatic improvement was noted. In hepatic applications, intravenous glutathione is used clinically in several jurisdictions as adjunctive therapy for drug-induced liver injury and for the potentiation of NAC in acetaminophen toxicity, where the glutathione-NAPQI conjugation pathway is the principal detoxification mechanism. In dermatology, oral and intravenous glutathione have been studied for skin lightening through inhibition of tyrosinase and melanin biosynthesis, with modest clinical evidence supporting efficacy at doses of 250 to 500 mg.

This monograph reviews the chemistry, biosynthesis, and compartmental distribution of glutathione; the enzymatic mechanisms of the glutathione-dependent antioxidant and conjugation systems; the pharmacokinetics and bioavailability considerations across oral, intravenous, liposomal, and sublingual routes; the preclinical pharmacology in models of neurodegeneration, hepatotoxicity, and inflammation; the clinical evidence base across neurological, hepatic, immunological, and dermatological indications; sourcing and quality verification considerations for research applications; reconstitution and handling; stack interactions with other redox-active compounds and pharmaceuticals; an adverse-event and safety profile; and a comparative assessment of five alternative glutathione-elevating strategies (N-acetylcysteine, S-acetyl-L-glutathione, liposomal glutathione, alpha-lipoic acid, and whey protein isolate) against reduced glutathione on five competency standards (bioavailability, effect size on tissue glutathione stores, clinical evidence breadth, side-effect profile, and overall validation).